HAVCR2 and cancer: As TIM-3 has a negative impact on immune regulation, the blockade of TIM-3 inhibition using an antibody may induce an antitumor immune response against some cancers, such as colorectal cancer, in which anti-CTLA-4 and anti-PD-1 antibodies were not effective [126].